NEW YORK (
) is trading at unusually high volume Thursday with 4.1 million shares changing hands. It is currently at four times its average daily volume and trading down $2.66 (-7%) at $35.63 as of 2:30 p.m. ET.
BioMarin has a market cap of $4.52 billion and is part of the
industry. Shares are up 11.4% year to date as of the close of trading on Wednesday.
BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and rest of the world.
TheStreet Ratings rates BioMarin as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and weak operating cash flow. You can view the full
See all heavy volume stocks in our
or get investment ideas from our